Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30133% above fair value
$162.18−0.60 (-0.37%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Repligen gross margin
Gross margin is gross profit as a percentage of revenue.
Repligen's gross margin for the twelve months ending Sep 30, 2026 was 53.5%. For fiscal 2025 it was 52.3%, against 43.3% the year before. The highest annual figure on record is 80.2% in fiscal 2010.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 52.3% | +9.0 |
| FY2024 | Dec 31, 2024 | 43.3% | −0.7 |
| FY2023 | Dec 31, 2023 | 44.0% | −12.8 |
| FY2022 | Dec 31, 2022 | 56.9% | −1.5 |
| FY2021 | Dec 31, 2021 | 58.3% | +1.1 |
| FY2020 | Dec 31, 2020 | 57.2% | +1.3 |
| FY2019 | Dec 31, 2019 | 55.9% | +0.5 |
| FY2018 | Dec 31, 2018 | 55.4% | +2.9 |
| FY2017 | Dec 31, 2017 | 52.5% | −2.4 |
| FY2016 | Dec 31, 2016 | 54.9% | −2.9 |
| FY2015 | Dec 31, 2015 | 57.8% | +1.9 |
| FY2014 | Dec 31, 2014 | 55.9% | −11.1 |
| FY2013 | Dec 31, 2013 | 67.0% | −12.5 |
| FY2011 | Mar 31, 2011 | 79.6% | −0.6 |
| FY2010 | Mar 31, 2010 | 80.2% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 53.0% | −0.2 |
| Q2 FY2026 | Jun 30, 2026 | 53.9% | +2.9 |
| Q1 FY2026 | Mar 31, 2026 | 55.7% | +1.7 |
| Q4 FY2025 | Dec 31, 2025 | 51.2% | +28.0 |
| Q3 FY2025 | Sep 30, 2025 | 53.2% | +3.2 |
| Q2 FY2025 | Jun 30, 2025 | 51.0% | −0.3 |
| Q1 FY2025 | Mar 31, 2025 | 54.0% | +3.9 |
| Q4 FY2024 | Dec 31, 2024 | 23.2% | −23.9 |
| Q3 FY2024 | Sep 30, 2024 | 50.0% | +24.1 |
| Q2 FY2024 | Jun 30, 2024 | 51.3% | +1.2 |
| Q1 FY2024 | Mar 31, 2024 | 50.1% | −0.4 |
| Q4 FY2023 | Dec 31, 2023 | 47.1% | −4.3 |
| Q3 FY2023 | Sep 30, 2023 | 25.9% | −31.0 |
| Q2 FY2023 | Jun 30, 2023 | 50.2% | −8.3 |
| Q1 FY2023 | Mar 31, 2023 | 50.5% | −9.6 |
| Q4 FY2022 | Dec 31, 2022 | 51.4% | −4.6 |
| Q3 FY2022 | Sep 30, 2022 | 56.9% | −0.7 |
| Q2 FY2022 | Jun 30, 2022 | 58.5% | −3.5 |
| Q1 FY2022 | Mar 31, 2022 | 60.1% | +1.9 |
| Q4 FY2021 | Dec 31, 2021 | 56.0% | +0.3 |
| Q3 FY2021 | Sep 30, 2021 | 57.6% | −0.2 |
| Q2 FY2021 | Jun 30, 2021 | 62.0% | +4.1 |
| Q1 FY2021 | Mar 31, 2021 | 58.2% | +0.2 |
| Q4 FY2020 | Dec 31, 2020 | 55.7% | −1.0 |
| Q3 FY2020 | Sep 30, 2020 | 57.9% | +3.1 |
| Q2 FY2020 | Jun 30, 2020 | 57.9% | +1.3 |
| Q1 FY2020 | Mar 31, 2020 | 58.0% | +2.2 |
| Q4 FY2019 | Dec 31, 2019 | 56.6% | +2.1 |
| Q3 FY2019 | Sep 30, 2019 | 54.7% | −0.5 |
| Q2 FY2019 | Jun 30, 2019 | 56.6% | +0.7 |
| Q1 FY2019 | Mar 31, 2019 | 55.7% | −0.4 |
| Q4 FY2018 | Dec 31, 2018 | 54.6% | +0.6 |
| Q3 FY2018 | Sep 30, 2018 | 55.2% | +9.9 |
| Q2 FY2018 | Jun 30, 2018 | 55.8% | −1.2 |
| Q1 FY2018 | Mar 31, 2018 | 56.1% | +1.9 |
| Q4 FY2017 | Dec 31, 2017 | 54.0% | +1.5 |
| Q3 FY2017 | Sep 30, 2017 | 45.4% | – |
| Q2 FY2017 | Jun 30, 2017 | 57.1% | – |
| Q1 FY2017 | Mar 31, 2017 | 54.3% | – |
| Q4 FY2016 | Dec 31, 2016 | 52.5% | – |
See a number that looks wrong?